Exabis Library
Welcome to the e-CCO Library!
P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P435: Effectiveness of therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease patients. Systematic review and meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P435: High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohort
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P435: Liver injury associated with anti-tumour necrosis factor therapy in paediatric irritable bowel disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P435: Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P435: Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P435: The impact of perianal fistula in Crohn’s disease on quality of life: results of a patient survey conducted in Europe
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P435: The mean corpuscular volume flow – prognostic value for inflammatory bowel disease under thiopurine treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P436: Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P436: Darvadstrocel treatment outcomes in Crohn’s disease patients with complex perianal fistulas: the role of TNFi co-treatment in ADMIRE CD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P436: Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P436: Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P436: SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapse
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM